Crescent Biopharma (CBIO)
Develops antibody medicines for solid tumors through bispecific and ADC programs.
$18.27
Pre-market−0.24 (−1.30%)
At close$18.51(+3.23%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions60 holders · as of Mar 31, 2026 | 67.61% | 25.11M shares | |
| Insiders8 holders · as of Jun 23, 2026 | 1.56% | 580.4K shares | |
| Strategic holders1 holder · as of Jun 10, 2019 | 0.13% | 47.7K shares | |
| Otherremainder | 30.70% | 11.40M shares |
37.14M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
60 holders · 25.11M shares · 18 new positions · 34 increased · 8 reduced · 12 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 4.13M | 11.13% | 0 | May 15, 2026 |
| BVF Inc/IL | 2.75M | 7.40% | 0 | May 15, 2026 |
| Fairmount Funds Management LLC | 2.75M | 7.40% | 0 | May 15, 2026 |
| VR Adviser, LLC | 2.13M | 5.74% | 0 | May 15, 2026 |
| FCPM Iii Services B.V. | 1.68M | 4.52% | 0 | May 15, 2026 |
| Balyasny Asset Management L.P. | 1.51M | 4.07% | +1.40M | May 15, 2026 |
| Vestal Point Capital, LP | 1.50M | 4.04% | 0 | May 15, 2026 |
| Opaleye Management Inc. | 1.31M | 3.53% | +134.3K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Peter Harwinincl. Fairmount Funds Management LLC, Tomas Kiselak +1 more | 16.52% | 6.60M | 13D | Jul 20, 2026 ↗ |
| FMR LLC | 15.00% | 4.13M | 13G | Feb 5, 2026 ↗ |
| Arsani Williamincl. Logos Global Management LP, Logos Global Management GP LLC +2 more | 11.00% | 13G | Nov 27, 2024 ↗ | |
| 1Globe Capital LLC | 10.30% | 1.43M | 13G | Oct 14, 2025 ↗ |
| Venrock Healthcare Capital Partners III, L.P. | 9.90% | 1.39M | 13G | Jun 23, 2025 ↗ |
| RA Capital Healthcare Fund, L.P.incl. Rajeev Shah, Peter Kolchinsky +1 more | 9.90% | 13G | Nov 6, 2024 ↗ | |
| ForGrowth III PA B.V. | 6.10% | 1.68M | 13G | Dec 11, 2025 ↗ |
| Balyasny Asset Management L.P. | 5.48% | 1.51M | 13G | May 15, 2026 ↗ |
| Vestal Point Capital, LP | 5.40% | 1.50M | 13G | Feb 17, 2026 ↗ |
| Biotechnology Value Fund L P | 5.10% | 707.1K | 13G | Aug 14, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 16, 2026 | Fairmount Funds Management LLCdirector, 10 percent owner: | Purchase · 2 lots | 1,379,347 | $8.97 | 5,895,353 |
| Jun 22, 2026 | Joshua T. Brummdirector, officer: Chief Executive Officer | Sale | 42,305 | $17.99 | 281,212 |
| Jun 22, 2026 | Jonathan McNeillofficer: President and COO | Sale | 20,549 | $17.99 | 139,158 |
| Jun 22, 2026 | Ellie Eunkyung Imofficer: Chief Medical Officer | Sale | 1,219 | $17.99 | 22,069 |
| Jun 22, 2026 | Barbara Harlin Bisphamofficer: See Remarks | Sale | 1,218 | $17.99 | 19,330 |
| Jun 22, 2026 | Richard William Scalzoofficer: Chief Financial Officer | Sale | 1,112 | $17.99 | 20,298 |
| Jun 22, 2026 | Jan Pinkasofficer: Chief Scientific Officer | Sale | 1,288 | $17.99 | 22,239 |
| Jun 22, 2026 | Ryan Lynchofficer: See Remarks | Sale | 465 | $17.99 | 13,871 |
| Dec 4, 2025 | Fairmount Funds Management LLCdirector, 10 percent owner: | Purchase · 2 lots | 1,491,434 | $12.23 | 4,516,006 |
CongressHouse and Senate disclosures
Not reported.